Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography

G Künig; K L Leenders; R Sanchez-Pernaute; A Antonini; P Vontobel; A Verhagen; I Günther

Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography

Ann Neurol. 2000 May;47(5):644-8.

Authors

G Künig¹, K L Leenders, R Sanchez-Pernaute, A Antonini, P Vontobel, A Verhagen, I Günther

Affiliation

¹ PSI, Paul Scherrer Institut, PET Program, Villigen, Switzerland.

PMID: 10805336

Abstract

We used positron emission tomography and [11C]flumazenil to analyze the benzodiazepine receptor binding in symptomatic and asymptomatic carriers of the Huntington's disease gene. We found an inverse relationship between [11C]flumazenil and [11C]raclopride binding in the putamen of symptomatic patients, and interpret this result as GABA receptor upregulation.

MeSH terms

Adult
Carbon Radioisotopes
Caudate Nucleus / diagnostic imaging
Caudate Nucleus / metabolism*
Dopamine Antagonists / pharmacokinetics
Female
Flumazenil / pharmacokinetics*
GABA Modulators / pharmacokinetics*
Humans
Huntington Disease / diagnostic imaging*
Huntington Disease / metabolism
Male
Middle Aged
Putamen / diagnostic imaging
Putamen / metabolism*
Raclopride / pharmacokinetics
Receptors, GABA-A / metabolism*
Tomography, Emission-Computed*

Substances

Carbon Radioisotopes
Dopamine Antagonists
GABA Modulators
Receptors, GABA-A
Flumazenil
Raclopride